Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment

< Back to All Resources

Neonatal abstinence syndrome, which occurs as a result of in utero opioid exposure, affects between 6.0 and 20 newborns per 1000 live US births. There is substantial variability in how neonatal abstinence syndrome is diagnosed and managed. This article summarizes the key findings of NAS studies from the past 10 years (2007-2017).

Related Topics

  • Behavioral Health
  • Children 0-5
  • Medications for Addiction Treatment (MAT)
  • Medical Care
  • Neonatal Abstinence Syndrome (NAS)